

References :

1. Stebbing J, Gazzard B, Douek DC. Where does HIV live? *The New England journal of medicine*. 2004;350(18):1872-80.
2. UNAIDS. UNAIDS report on the global AIDS epidemic 2013. [web page] 2013; 198]. Available from: www.unaids.org/.../unaids/.../2013/gr2013/UNAIDS_Global_Report_2013.
3. Commision INA. Republik Indonesia Country Report on the Follow up to the Declaration of Commitment on HIV/AIDS (UNGASS). 2012; Available from: www.unaids.org/en/dataanalysis/.../ce_ID_Narrative_Report.pdf.
4. Laksono A. National HIV and AIDS Strategy and Action Plan 2010-2014. 2011; Available from: www.ilo.org/.../wcms_173075.pdf.
5. Indonesia MoH. Cases of HIV/AIDS in Indonesia Reported thru' December 2013. 2013; Available from: www.spiritia.or.id/Stats/StatCurr.php?lang=id&gg=1.
6. UNAIDS. UNAIDS REPORT ON THE GLOBAL AIDS EPIDEMIC | 2010 2010. Available from: www.unaids.org/documents/20101123_GlobalReport_em.pdf.
7. Situasi pengobatan ARV di Indonesia [database on the Internet]. 2013. Available from: spiritia.or.id/Stats/statart.php?lang=id.
8. Phenix BN, Pahwa S. Immune Activation In: Badley AD, editor. *Cell Death During HIV Infection*. United States: CRC Press; 2010. p. 174.
9. Alimonti J. Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. *Journal of General Virology*. 2003;84(7):1649-61.
10. Février M, Dorgham K, Rebollo A. CD4+ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis. *Viruses*. 2011;3(5):586-612.
11. Streeck H, Nixon DF. T cell immunity in acute HIV-1 infection. *The Journal of infectious diseases*. 2010;202 Suppl 2(Suppl 2):S302-8.
12. Jekle A, Keppler OT, Clercq ED, Weinstein M, Goldsmith MA. In Vivo Evolution of Human Immunodeficiency Virus Type 1 toward Increased Pathogenicity through CXCR4-Mediated Killing of Uninfected CD4 T Cells. *Journal of Virology*. 2003;77:5846-54.
13. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. *Annual review of immunology*. 2003;21:265-304.
14. WHO. Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS. New Delhi. 2007. Available from: http://www.searo.who.int/LinkFiles/BCT_HLM-392.pdf.

15. Bosco KF. Evaluation of the accuracy of the CD4+ T-cell counts using PIMA™ CD4 as compared to BD FACScaliber Flow Cytometry. Kampala Uganda: Makerere University; 2010.
16. Olteanu H, Schur BC, Harrington AM, Kroft SH. Time and temperature stability of T-cell subsets evaluated by a dual-platform method. *Am J Blood Res* 2012;2(2):128-35.
17. Shete A, Thakar M, Abraham PR, Paranjape R. A review on peripheral blood CD4+ T lymphocyte counts in healthy adult Indians. *Indian J Med Res* 2010;132:667 - 75.
18. Pattanapanyasat K, Thakar MR. CD4+ T cell count as a tool to monitor HIV progression & anti-retroviral therapy. *The Indian journal of medical research*. 2005;121(4):539-49.
19. Lederman MM, Rodriguez B, Sieg S. Immunopathogenesis of HIV Infection. San Francisco: University of California; 2004 [updated 2006]; Available from: <http://hivinsite.ucsf.edu/InSite?page=kb-00&doc=kb-02-01-04>.
20. Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality. *PLOS Pathogens*. 2014;10(5):e1004078.
21. Wua R, Owen GC, Liuc T, Shena G-Q, Morrissa RI. Significance of the detection of HIV-1 gag- and/or pol-CD8/A2 T-lymphocytes in HIV-patients. *Immunology Letters* 98 (2005) 73–81. 2005;98:73-81.
22. Musyoki S, Mining S, Nyongesa P. Level of CD8 T Lymphocytes Activation in HIV-Infected Pregnant Women: In the Context of CD38 and HLA-DR Activation Markers. *Interdisciplinary Perspectives on Infectious Diseases*. 2014.
23. Bradley Hare C. Clinical Overview of HIV Disease. University of California San Francisco.2009 [cited 2014 June,6]; Available from: <http://hivinsite.ucsf.edu/InSite?page=kb-00&doc=kb-03-01-01>.
24. Z. Zhang, S. Hu, J. Liu. CD4+CD38+HLA-DR+Cells: a predictor of viral set point in Chinese men with primary HIV infection who have sex with men. *Japanese Journal of Infectious Diseases*. 2011;64(5):423–5.
25. Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection : an epiphenomenon of T-cell activation or an active player in virus / host interactions ? *AIDS*. 2000;14:1079-89.
26. Giorgi JV, Lyles RH, Matud JL, Yamashita TE, Mellors JW, Hultin LE, et al. Predicted Valued of Immunologic and Virologic Marker After Long or Short Duration of HIV-1 Infection. *Journal of Acquired Immune Deficiency Syndromes*. 2002;29:346-55.

27. Onlamoon N, Tabprasit S, Suwanagool S, Louisirootchanaikul S, Ansari Aa, Pattanapanyasat K. Studies on the potential use of CD38 expression as a marker for the efficacy of anti-retroviral therapy in HIV-1-infected patients in Thailand. *Virology*. 2005;341:238-47.
28. Resino S, Bello M, Gurbindo MD. CD38 Expression in CD8 + T Cells Predicts Virological Failure in HIV Type 1 – Infected Children Receiving Antiretroviral Therapy. *Clinical Infectious Disease*. 2004;38:412-7.
29. Shin D-h, Martinez SS, Parsons M, Jayaweera DT, Campa A, Baum MK. Relationship of Oxidative Stress with HIV Disease Progression in HIV/HCV Co-infected and HIV Mono-infected Adults in Miami. *International Journal of Bioscience, Biochemistry and Bioinformatics*. 2012;2(3):217-23.
30. Pace GW, Leaf CD. The role of oxidative stress in HIV disease. *Free Radical Biology and Medicine*. 1995;19(4):523-8.
31. Peterhans E. Oxidants and Antioxidants in Viral Diseases: Disease Mechanisms and Metabolic Regulation. *The Journal of Nutrition*. 1997;127(5):962S-5S.
32. Mandas A, Iorio EL, Congiu MG, Balestrieri C, Mereu A, Cau D, et al. Oxidative Imbalance in HIV-1 Infected Patients Treated with Antiretroviral Therapy. *Journal of Biomedicine and Biotechnology*. 2009;2009:1-7.
33. Blas-Garcia A, Apostolova N, Esplugues JV. Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs: Clinical Implications. *Current Pharmaceutical Design*. 2011;17:4076-86.
34. Kashou AH, Agarwal A. Oxidants and Antioxidants in the Pathogenesis of HIV / AIDS. *The Open Reproductive Science Journal*. 2011;3:154-61.
35. Palakawong C, Sophanodora P, Pisuchpen S, Phongpaichit S. Antioxidant and antimicrobial activities of crude extracts from mangosteen (*Garcinia mangostana* L.) parts and some essential oils. *International Food Research Journal*. 2010;17:583-9.
36. Chin Y-W, Kinghorn AD. Structural Characterization, Biological Effects, and Synthetic Studies on Xanthenes from Mangosteen (*Garcinia mangostana*), a Popular Botanical Dietary Supplement. *Mini-Reviews in Organic Chemistry*. 2008;5:355-64.
37. Miwako K, Liliang Z, Hongping J, Yan K, Boxin O. Bioavailability and Antioxidant Effects of a Xanthone-Rich Mangosteen (*Garcinia mangostana*) Product in Humans. *Journal of Agricultural and Food Chemistry*. 2009;57:8788-92.
38. Jung HA, Su BN, Keller WJ, Mehta RG, Kinghorn AD. Antioxidant Xanthenes from the Pericarp of *Garcinia mangostana* (Mangosteen). *Journal of Agricultural and Food Chemistry*. 2006;54:2077-82.

39. Pedraza-Chaverri J, Cardenas-Rodriguez N, Orozco-Ibarra M, Perez-Rojas JM. Medicinal properties of mangosteen (*Garcinia mangostana*). *Food and Chemical Toxicology*. 2008;46:3227-39.
40. Chen S-X, Wan M, Loh B-N. Active Constituents Against HIV-1 Protease from *Garcinia mangostana*. *Planta Medica*. 1996;62(4):381-2.
41. Vlietinck aJ, De Bruyne T, Apers S, Pieters La. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. *Planta Medica*. 1998;64(2):355-64.
42. Cos P, Maes L, Vlietinck A, Pieters L. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection - an update (1998 - 2007). *Planta Medica*. 2008;74(11):1323-37.
43. Tang Y-P, Li P-G, Kondo M, Ji H-P, Kou Y, Ou B. Effect of a mangosteen dietary supplement on human immune function: a randomized, double-blind, placebo-controlled trial. *Journal of medicinal food*. 2009;12:755-63.
44. Hunt R. Human Immunodeficiency Virus and AIDS. the University of South Carolina school of medicine; 2009 [updated July 10, 2010; cited 2014 June 20]; Available from: <http://pathmicro.med.sc.edu/lecture/hiv6.htm>.
45. Bennett NJ. HIV Disease. 2014 [updated may 27, 2014; cited 2014 June,6]; Available from: <http://emedicine.medscape.com/article/211316-overview#aw2aab6b2b1aa>.
46. Siliciano RF. Acquired Immune Deficiency Syndrome (AIDS). Encyclopedia of Life Sciences [Internet]. 2001 [cited 2014 June,06]:[1-12 pp.]. Available from: immuneweb.xmu.edu.cn/reading/Clinic/3.pdf.
47. Barré-Sinoussi F. HIV as the cause of AIDS. *The Lancet*. 1996;348:31-5.
48. Levi JA. Virus and Host Factors in HIV Pathogenesis. medscape allergy and clinical immunology; 2003 [cited 2014 June, 30]; Available from: <http://www.medscape.org/viewarticle/459845>.
49. Mugwagwa T. The Role of CD8 immune responses in HIV infection. Cape Town: University of Cape Town; 2004.
50. Pilcher CD, Eron JJ, Galvin S, Gay C, Cohen MS. Acute HIV revisited: new opportunities for treatment and prevention. *The Journal of clinical investigation*. 2004;113:937-45.
51. Munier ML, Kelleher AD. Acutely dysregulated, chronically disabled by the enemy within: T-cell responses to HIV-1 infection. *Immunology and cell biology*. 2007;85:6-15.
52. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. *AIDS*. 2008;22:439-46.

53. Catalfamo M, WilhelmLu C, Tcheung e, Proschan M, Friesen T, Park J-H, et al. CD4 and CD8 T Cell Immune Activation during Chronic HIV Infection: Roles of Homeostasis, HIV, Type I IFN, and IL-7. *The Journal of Immunology*. 2011;186:2106-16.
54. Catalfamo M, Mascio MD, Hu Z, Srinivasula S, Thakera V, Adelsberger J, et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. *PNAS*. 2008;105(50):19851–6.
55. Mishra S, Dwivedi SP, Dwivedi N, Singh RB. Immune Response and Possible Causes of CD4+T-cell Depletion in Human Immunodeficiency Virus (HIV) - 1 Infection. *The Open Nutraceuticals Journal*. 2009;2(1):46-51.
56. Kestens L. The immune system and HIV. 2005 [cited 2014 June,06]; Available from: <http://www.aidsmap.com>.
57. Trautmann L, Mbitikon-Kobo F-M, Goulet J-P, Peretz Y, Shi Y, Grevenynghe JV, et al. Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. *Blood*. 2012;120(17):3466-77.
58. Liu Z, Cumberland W, Hultin L, Kaplan A, Detels R, Giorgi J. CD8+ T lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. *J Acq Immun Deficienc & Hum Retrovirol*. 1998;18:332-40.
59. Almeida M, Cordero M, Almeida J, Lopez A, Orfao A. CD38 on peripheral blood cells: The value of measuring CD38 expression on CD8 T-cells in patients receiving highly active anti-retroviral therapy. *Clinical and Applied Immunology Reviews* 2002;2:307-20.
60. Hultin L, Matud J, Giorgi J. Quantitation of CD38 activation antigen expression on CD8+ T cells in HIV-1 infection using CD4 expression on CD4+ T lymphocytes as a biological calibrator. *Cytometry*. 1998;33:123-32.
61. Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, et al. Characterization of Viral Dynamics in Human Immunodeficiency Virus Type 1- Infected Patients Treated with Combination Antiretroviral Therapy : Relationships to Host Factors, Cellular Restoration, and Virologic End Points. *The Journal of Infectious Diseases*. 1999;179:799–807.
62. WHO. Antiretroviral therapy. 2014 [cited 2014 July 02]; Available from: http://www.who.int/topics/antiretroviral_therapy/en/.
63. Maggiolo F, Leone S. CD4+ T Lymphocyte Recovery in Individuals with Type-1 Human Immunodeficiency Virus Infection. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2010;51(4):465-7.

64. WebMD. HIV: Antiretroviral Therapy (ART) - Topic Overview. 2012 [updated October 22, 2012; cited 2014 July 02]; Available from: <http://www.webmd.com/hiv-aids/tc/hiv-highly-active-antiretroviral-therapy-haart-topic-overview>.
65. WHO. Consolidated Guidelines on the use of Antiretroviral Drugs for treating and preventing HIV infection : recommendations for a public health approach. Switzerland 2013 [cited 2014 July 03]. Available from: <http://www.who.int/hiv/pub/guidelines/arv2013/download/en/>.
66. Hunt PW, Martin JN, Sinclair E, Brecht B, Hagos E, Lampiris H, et al. T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy. *The Journal of Infectious Diseases*. 2003;187:1534-43.
67. Steel A, John L, Shamji MH, Henderson DC, Gotch FM, Gazzard BG, et al. CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy. *HIV medicine*. 2008;9(2):118-25.
68. Sharma B. Oxidative Stress in HIV Patients receiving Antiretroviral Therapy. *Current HIV research*. 2014;12:1-9.
69. Repetto M, Reides C, Gomez Carretero ML, Costa M, Griemberg G, Llesuy S. Oxidative stress in blood of HIV infected patients. *Clinica chimica acta; international journal of clinical chemistry*. 1996;255:107-17.
70. Gil L, Martínez G, González I, Tarinas A, Álvarez A, Giuliani A, et al. Contribution to characterization of oxidative stress in HIV/AIDS patients. *Pharmacological Research*. 2003;47(3):217-24.
71. Mate JM, Aledo JC, Pe C, Esteban A, Segura JM. Interrelationship between oxidative damage and antioxidant enzyme activities : an easy and rapid experimental approach. *Biochemical Education*. 2000;28:93-5.
72. Gil L, Lewis L, Martínez G, Tarinas A, González I, Alvarez A, et al. Effect of increase of dietary micronutrient intake on oxidative stress indicators in HIV/AIDS patients. *International journal for vitamin and nutrition research*. 2005;75:19-27.
73. Aquaro S, Scopelliti F, Pollicita M, Perno CF. Oxidative Stress and HIV Infection: Target Pathways for Novel Therapies? : *medscape allergy and clinical immunology*; 2008 [cited 2014 July 07]; Available from: http://www.medscape.com/viewarticle/584032_1.
74. Westendorp M, Shatrov VA, Schulze-osthoff K, Frank R, Kraft M, Los M, et al. HIV-1 Tat potentiates TNF-induced NF-KB activation and cytotoxicity by altering the cellular redox state. *The EMBO Journal*. 1995;14(3):546-54.

75. Oguntibeju OO, Heever WMJVD, Schalkwyk FEV. Immune response and possible causes of CD4 + T-cell depletion in human immunodeficiency virus (HIV) -1 infection. *African Journal of Microbiology Research*. 2009;3(7):344-52.
76. Obolskiy D, Pischel I, Siriwatanametanon N, Heinrich M. Garcinia mangostana L.: a phytochemical and pharmacological review. *Phytotherapy Research*. 2009;23(8):1047-65.
77. Walker EB. HPLC analysis of selected xanthenes in mangosteen fruit. *Journal of Separation Science*. 2007;30(9):1229-34.
78. Haytowitz DB, Bhagwat S. USDA Database for the Oxygen Radical Absorbance Capacity (ORAC) of Selected Foods, Release 2. Baltimore: *U.S. Department of Agriculture*; 2010 [cited 2014 July 08]; Available from: www.orac-info-portal.de/download/ORAC_R2.pdf.
79. Gutierrez-Orozco F, Failla ML. Biological Activities and Bioavailability of Mangosteen Xanthenes: A Critical Review of the Current Evidence. *Nutrients*. 2013;5(8):3163-83.
80. Chitchumroonchokchai C, Riedl KM, Suksumrarn S, Clinton SK, Kinghorn AD, Failla ML. Xanthenes in Mangosteen Juice Are Absorbed and Partially Conjugated by Healthy Adults. *The Journal of Nutrition*. 2012;142:675–80.
81. Li L, Han A-R, Kinghorn AD, Frye RF, Derendorf H, Butterweck V. Pharmacokinetic Properties of Pure Xanthenes in Comparison to a Mangosteen Fruit Extract in Rats *Planta Medica* 2013;79(8):646-53.
82. Syamsudin, Faizatun, Rahayu L. HPLC Analysis Mangostin After Orally Administration in Rats. *Asian Journal of Chemistry*. 2010;22(9):6729-33.
83. Vishnu Priya V, Jainu M, Mohan SK, Karthik B, Saraswathi P, Chandra Sada Gopan V. Toxicity Study of Garcinia Mangostana Linn . Pericarp Extract in Rats. *Asian Journal of Experimental Biological Sciences*. 2010;1(3):633-7.
84. Chivapat S, Chavalittumrong P, Wongsinkongman P, Phisalpong C, Rungsipipat A. Chronic Toxicity Study of Garcinia mangostana Linn. pericarp Extract. *Thailand Journal Veterinary Medicine*. 2011;41(1):45-53.
85. Zieselman A. The Placebo Effect. *Dartmouth undergraduate journal of science* 2012:22-4.